Due to the heterogeneity of non-clear cell renal cell carcinoma (nccRCC), patients are frequently excluded from phase 3 trials focusing on clear cell RCC, resulting in limited treatment options for those with nccRCC. Francesco Massari, MD, PhD, MSc, and colleagues developed the ARON-1 study to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) versus immuno-oncology (IO)-based combinations in patients with papillary RCC (pRCC), the most common histological subtype of nccRCC. ...
nccRCC
Advertisement
The investigators found significant differences in OS and recurrence-free survival across the histological subtypes.
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Researchers noted that following first-line TKI therapy, effective subsequent treatment options for nccRCC were unclear.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
While advances have improved understanding of molecular targets, optimal management of nccRCC remains unclear.
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Advertisement
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
